$190.00
Overview
Retatrutide is the most advanced metabolic research compound currently in clinical development. A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it surpasses the mechanism of both semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) by adding glucagon receptor activation — which directly increases energy expenditure and raises metabolic rate at rest. Phase 2 clinical data has demonstrated up to approximately 24% body weight reduction, approaching bariatric surgery outcomes.
What it does
GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation improves insulin secretion and metabolic function. Glucagon receptor activation is the key differentiator — it increases caloric expenditure even at rest by stimulating fat oxidation and thermogenesis through brown adipose tissue, a mechanism not present in prior GLP-1 therapies. The combined effect targets energy intake, energy expenditure, and metabolic efficiency simultaneously.
Research areas
Obesity and significant weight reduction research · Metabolic syndrome · Insulin resistance · Body recomposition · Next-generation GLP-1 comparator research · NASH and hepatic fat reduction
Key facts
| Form | Lyophilised powder — requires reconstitution with bacteriostatic water |
| Storage | Lyophilised: -20°C. Reconstituted: 2–8°C, use within 28 days |
| Purity | ≥99% — third-party COA verified, batch-specific documentation included |
| Status | Currently in Phase 3 clinical trials — not FDA approved |
For research use only. Not for human consumption. This product is not approved for human use by the FDA or any regulatory body.
